Posted by Michael Wonder on 20 Dec 2022
Qiagen receives FDA approval for companion diagnostic to Mirati Therapeutics’ Krazati in non-small-cell lung cancer
13 December 2022 - therascreen KRAS RGQ PCR kit approved as a companion diagnostic to aid in identifying non-small-cell lung cancer patients eligible for treatment with Krazati (adagrasib).
Qiagen has announced the US FDA approval of its therascreen KRAS RGQ PCR kit (therascreen KRAS kit) as a companion diagnostic test to Mirati Therapeutic’s drug Krazati (adagrasib) for non-small-cell lung cancer.
